GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Medisan Pharmaceutical Co Ltd (SZSE:002900) » Definitions » EBITDA Margin %

Harbin Medisan Pharmaceutical Co (SZSE:002900) EBITDA Margin % : -13.47% (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Harbin Medisan Pharmaceutical Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Harbin Medisan Pharmaceutical Co's EBITDA for the three months ended in Mar. 2025 was ¥-28 Mil. Harbin Medisan Pharmaceutical Co's Revenue for the three months ended in Mar. 2025 was ¥205 Mil. Therefore, Harbin Medisan Pharmaceutical Co's EBITDA margin for the quarter that ended in Mar. 2025 was -13.47%.


Harbin Medisan Pharmaceutical Co EBITDA Margin % Historical Data

The historical data trend for Harbin Medisan Pharmaceutical Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Medisan Pharmaceutical Co EBITDA Margin % Chart

Harbin Medisan Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.14 59.82 16.46 17.94 17.88

Harbin Medisan Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.57 3.80 8.20 9.72 -13.47

Competitive Comparison of Harbin Medisan Pharmaceutical Co's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Medisan Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harbin Medisan Pharmaceutical Co's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harbin Medisan Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Harbin Medisan Pharmaceutical Co's EBITDA Margin % falls into.


;
;

Harbin Medisan Pharmaceutical Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Harbin Medisan Pharmaceutical Co's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=202.452/1132.477
=17.88 %

Harbin Medisan Pharmaceutical Co's EBITDA Margin % for the quarter that ended in Mar. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=-27.625/205.028
=-13.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harbin Medisan Pharmaceutical Co  (SZSE:002900) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Harbin Medisan Pharmaceutical Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Harbin Medisan Pharmaceutical Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Medisan Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Beijing Road, Limin Development Zone, Heilongjiang Province, Harbin, CHN, 150025
Harbin Medisan Pharmaceutical Co Ltd is the pharmaceutical manufacturing company. It is engaged in the research, development, manufacturing and sales of chemical preparations. The main products are oxiracetam injection, mirtazapine tablets, valsartan dispersible tablets, injection brain drugs such as protein hydrolysate, glucose injection and sodium chloride injection. The company is also involved in research, development, production and sales of medical devices.
Executives
Fan Qing Ji Executives
Zhao Qing Fu Directors, Directors, and Executives
Liang Yan Fei Directors, executives
Yao Fa Xiang Executives
Wang Ming Xin Executives

Harbin Medisan Pharmaceutical Co Headlines

No Headlines